Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
PET imaging in MSK infections
Published in: Nuclear Medicine and Molecular Imaging
Access to document
10.1016/B978-0-12-822960-6.00071-5
document
Musculoskeletal infections are highly feared, form a major burden on healthcare, and may lead to severe morbidity and mortality. The diagnosis may be difficult with non-specific symptoms requiring multiple diagnostic investigations. FDG-PET/CT is one of them showing good diagnostic accuracy in most musculoskeletal infections. However, one has to be aware of the non-specific FDG uptake in patients with metallic implants and in the postsurgical phase. In this chapter, the advantages and disadvantages of the use of FDG-PET/CT in musculoskeletal infections in described for several indications: infections in the...
Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.22.00400
document
PURPOSE: Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis. METHODS: In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to...
IMPACT-Metastatic Breast Consortium, Jasper J L van Geel, Jorianne Boers, Sjoerd G Elias, Andor W J M Glaudemans, Erik F J de Vries, Geke A P Hospers, Michel van Kruchten, Evelien J M Kuip, Agnes Jager, Willemien C Menke-van der Houven van Oordt, Bert van der Vegt, Elisabeth G E de Vries, Carolina P Schröder
Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [F-18]FDG PET/CT features
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-021-05626-3
document
Background One of the challenges in the management of patients with follicular lymphoma (FL) is the identification of individuals with histological transformation, most commonly into diffuse large B-cell lymphoma (DLBCL). [F-18]FDG-PET/CT is used for staging of patients with lymphoma, but visual interpretation cannot reliably discern FL from DLBCL. This study evaluated whether radiomic features extracted from clinical baseline [F-18]FDG PET/CT and analyzed by machine learning algorithms may help discriminate FL from DLBCL. Materials and methods Patients were selected based on confirmed histopathological diagnosis of primary FL (n=44) or...
F Montes de Jesus, Y Yin, E Mantzorou-Kyriaki, X U Kahle, R J de Haas, D Yakar, A W J M Glaudemans, W Noordzij, T C Kwee, M Nijland
18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors: A pilot study
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.121.262368
document
Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 frequently induces tumor response in metastatic melanoma patients. However, tumor response often takes months and may be heterogeneous. Consequently, additional local treatment for non-responsive metastases may be needed, especially in the case of brain metastases. Non-invasive imaging may allow the characterization of (brain) metastases to predict response. This pilot study uses 18F-BMS986192 PET for PD-L1 expression to explore the variability in metastatic tracer uptake and its relation to tumor response, with a special focus on brain metastases. Methods: Metastatic melanoma patients underwent...
Houdini’s illusions: some acts are not what they seem to be
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.121.262631
document
Roelof J Bennink, Mathias Prokop, Andor W J M Glaudemans, Liesbeth Peters-Bax, Jasper H Helthuis, Arthur Adams, Peter R Kornaat, Adriaan A Lammertsma, Lenka M Pereira Arias-Bouda